16 November 2019
1300 794 893

What's false eyelashes got to do with it?

Tim Boreham
30 August 2019

McPherson’s (MCP) $2.15

An old leopard can change its beauty spots, as the supplier of prosaic items such as hair brushes and false eyelashes would attest.

This 159-year-old institution has spruced up its game, with a series of revamps and restructures, finally delivering rewards to patient shareholders.

With stabilising earnings and debt under control, McPherson’s is gaining favour for its generous dividend payouts and investors are taking notice.

Released on August 15 – a day when the market fell almost 3% – the company’s full year results pushed McPherson’s shares up 5.5c, or 8%.

This uplift was even more impressive, given the stock soared 19% when the numbers were pre-announced on July 23.

Dubbed a “cracking set of results” by one broker, McPherson’s underlying earnings grew 35% to $13.7 million, on a 7% revenue increase to $210m.

For the first time in years, the result was not blighted by abnormal losses.

“There are earnings and there are earnings and these are very high quality earnings,” enthuses chief numbers man Paul Witheridge.

A former global Coca Cola exec, Laurie McAllister has overseen a multi- faceted renovation since he assumed the uncomfortable CEO role in late 2016.

The key pillar in the turnaround effort has been re-positioning the company as a supplier in the$17 billion body beautiful business. Or as McAllister puts it: “a stealth-like focus on health wellness and beauty.”

McPherson’s well-known offerings include skincare brand Dr Leewin’s and the diverse A’kin, which purveys anything from hydrating water (is there any other kind?) to geranium and cedarwood deodorant.

The company has also shed low-margin agency businesses and has got rid of its misfit home appliance business that included the Euromaid and Baumatic brands.

While McPherson’s remains a key supplier to the supermarkets, it has also been bolstering its higher-margin shelf presence in the mega chemist chains.

Overall management has focused on its six biggest clients – Coles, Woolworths, Metcash, Priceline, Chemist Warehouse and the Terry White chemist chain.

Rather than haggling over margins and trading terms, McAllister says the company and the retailers are working harmoniously on joint business plans “to grow the pie collectively’’.

China and other Asian export markets beckon, especially with the higher-end beauty products.

Management expects China sales to grow to $27m in 2019-20, from a standing start of $7m in 2018. McPherson’s exclusive China agent ABM racked up $60m of Dr Leewin’s sales, a far cry from the $400,000 achieved in 2016-17.

Across the board, McPherson’s sales growth is outpacing the broader market in the grocery, health and beauty and household categories.

Marketing director Donna Chan singles out the Dr Leewin’s brand which had an “absolutely phenomenal” year with 125% revenue growth, outpacing the broader skincare market fourfold.

In China, one of its new collagen products sold 5,000 units in 68 seconds.

Granted, McPherson’s Multix-branded kitchen products – aluminium foil and cling wrap and baking paper – don’t exactly get pulses racing beyond the Masterchef crowd.

But even this category is showing growth, thanks to the rollout of a green-friendly range of freezer and lunch bags. The number one supplier of cotton buds, Swisspers has also boosted its eco credentials by removing plastic stems from the devices.

Meanwhile, McPherson’s key warehouse at Rosebery in inner Sydney is operating at only 50% capacity.

In pre-tax terms, management guides to a 10% earnings increment in the current year, despite the currency headwinds and relentless private label competition from the supermarkets.

As a goods’ importer, McPherson’s regularly has been pummelled by a weak Aussie dollar but this time around the company has hedged its currency needs for the next 12 months.

“We are also getting the benefit of lower commodity costs, particularly with Multix,’’ says Witheridge.

McPherson’s net debt has shrunk from $77m in 2015 to $7.5m, which bodes well for the company’s ability to maintain a high dividend payout ratio while dispersing $20.7m of franking credits.

Despite the solid rerating the stock still trades on a yield of 5-6%.


Disclaimer: Under no circumstances have there been any inducements or like made by the company mentioned to either IIR or the author. The views here are independent and have no nexus to IIR’s core research offering. The views here are not recommendations and should not be considered as general advice in terms of stock recommendations in the ordinary sense.

If you liked this article you'll love the Switzer Report, our newsletter and website for trustees of self-managed super funds. Click here for a FREE trial and to hear more of Peter’s expert commentary and advice.

Let us know what you think
Get the latest financial, business, and political expert commentary delivered to your inbox.

When you sign up, we will never give away or sell or barter or trade your email address.

And you can unsubscribe at any time!
1300 794 893
© 2006-2019 Switzer. All Rights Reserved
homephoneenvelopedollargraduation-cap linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram